Amongst the human astrocytic tumours, the commonest of primary brain tumours, the clinical outcome of astrocytoma (AS) is signi®cantly better than anaplastic astrocytoma (AA) and glioblastoma multiforme (GBM). Often, low grade tumours can progress to or recur with a more malignant phenotype. Recent loss of heterozygosity (LOH) reports suspect the involvement of a tumour suppressor gene, dierent from p53, in the 17p13.3 region of the human chromosome. However, the eect of LOH of 17p13.3 region on tumour histology at presentation and prognosis is as yet unde®ned. As a ®rst step to de®ne the role of this putative oncogene in astrocytic tumour progression, we correlated the LOH of a locus, D17S379, in 17p13.3 region and the p53 locus in 17p13.1 region with the histopathology of astrocytic tumours by PCR based microsatellite and restriction fragment length polymorphism of DNA extracted from microdissected paran sections of 45 astrocytic tumours of dierent histopathological grades. LOH of D17S379 was signi®cantly associated (P=0.02) with AA and GBM (high grade malignancy), while no such preferential association was found with LOH of p53. There were no mutations in the exons 5 to 9 of p53 gene in the ®ve tumours with LOH of D17S379 but not of p53 region. In a case of AA with a heterogenous microscopic appearance, heterozygosity of D17S379 was lost only in the area with a more malignant histology while both areas had no LOH or mutation of p53. A locus at the 17p13.3 region, independent of the p53 locus, is involved in a large subset of astrocytic tumours during transformation into a more malignant phenotype, and thus may be a link in the chain of genetic events occurring in astrocytic tumour progression.
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Keywords: glioma,-genetics; chromosomes,-human,-pair 17; gene,-suppressor,-tumour Astrocytic tumours are the commonest primary tumours of the human brain and their outcome has not signi®cantly altered in spite of modern therapeutic modalities. Among these tumours, there is a striking dierence in the clinical outcome of AA and GBM with a median survival time of 50 weeks (Shapiro et al., 1986) as compared to AS with a median survival time of 6 yrs (Shaw et al., 1989) . Moreover, lower grades of tumours tend to recur as higher grades. The sequence of some of the genetic events that lead to astrocytic tumour progression from low grade to a higher grade has been derived (Louis and Gusella, 1995) from previous studies. Some of these are ampli®cation of the EGFR gene and deletions and mutations in the antioncogenes Rb and p16.
Consistent loss of heterozygosity of a de®ned region of the genome indicates the probable involvement of a tumour suppressor gene at that locus. In astrocytic tumours, LOH of 17p was commonly taken to imply the involvement of the p53 anti-oncogene. The LOH of 17p was found to be relatively frequent (30 ± 50%) and the remaining p53 allele was often (60 ± 70%) simultaneously mutated (Fults et al., 1992; Frankel et al., 1992) . The association of LOH of 17p13 region with p53 mutation in the other allele even in low grade astrocytomas (von Deimling et al., 1992) led to the conclusion that the involvement of p53 occurred early in glial or astrocytic tumorigenesis.
But, gradually, more reports came up showing that LOH of D17S5 (a locus telomeric to p53) can occur irrespective of LOH of p53. This led to the hypothesis of involvement of some other putative tumour suppressor genes of 17p distal to p53 (Frankel et al., 1992; Saxena et al., 1992) . However, in these studies, there was insucient and con¯icting evidence of any association of LOH at 17p13.3 with the histopathological grading and clinical outcome of the malignancy. In some studies (Fults et al., 1992; Lang et al., 1994) , the few low grade astrocytomas analysed were found to be without LOH at 17p13.3. These reports con¯ict with two other studies: in one (von Deimling et al., 1992) where 4/8 (50%) of low grade AS showed LOH of 17p13 and p53 mutations; in another (Hermanson et al., 1996) where 20% (5/25) low grade AS showed LOH of 17p13 with three of them having p53 mutations. In all the above studies, DNA from microdissected paran embedded tumour samples could not be used because of the limitation of the techniques used (Southern hybridization).
The signi®cance of the 17p13.3 locus has been highlighted by the recent identi®cation of a candidate tumour suppressor gene (Wales et al., 1995) , HIC-1, the suspected presence of a single or group of genes involved in cortical development and the discovery of two candidate tumour suppressor genes in ovarian carcinoma (Schultz et al., 1996) in this region.
We have analysed 21 AS, 3 AA and 21 GBM for LOH of D17S379 in 17p13.3 and p53 in 17p13.1 to obtain a pro®le of their involvement in astrocytic tumorigenesis. Tumour specimens were obtained after surgery and were ®xed and paran embedded routinely in the Pathology department. None of these cases received any pre-operative radiotherapy or chemotherapy. Four to ®ve consecutive 5 mm sections were cut from the blocks and the central section was stained by hematoxylin and eosin. Completely neoplastic areas as appropriate to the histopathological diagnosis and not contaminated by normal tissue were marked out in the stained slide by one of our experienced pathologist (MM or CS) and the same area was microdissected from the other slides after superimposition on the marked slide and the scrappings were stored. In a case where two distinct heterogenous areas were seen in tumour histology, the dierent areas were marked and collected separately. Leukocytes were isolated from peripheral blood of patients by ammonium chloride lysis of red blood cells and stored at 7708C, till further processing. DNA from microdissected tumour tissue and leukocyte was extracted according to established protocols (Largey et al., 1993) . Our use of microdissected samples with careful consideration to selecting appropriate areas of tumours not contaminated by normal tissue possibly has a bearing on the accuracy of subsequent results of allelotyping. The data being non-parametric, discrete (loss/no loss), two independent groups (AS and AA+GBM) type; Fisher's exact probability (P) test was carried out to assess the probability of association of the D17S379 or p53 loss with the dierent grades of astrocytic tumours just by pure chance. A P value of less than 0.05 was taken as signi®cant association.
Heterozygosity status of 17p13.3 locus
A polymorphic region containing dinucleotide repeats (D17S379) was PCR ampli®ed by primers (GAC CAC ATC TGT CCT CAC CTG T and CGA GTC CTC ACT GTA AACAAGG, one of them being 32 P end labelled) using published parameters (Carrozzo and Ledbetter, 1993) ; 1 min at 948C, 1 min at 558C, 30 s at 728C for 33 cycles; and analysed by autoradiography of a 6% denaturing polyacrylamide gel after electrophoresis.
10/23 (43%) clinically high grade tumours (AA and GBM) showed LOH of the D17S379 locus in the 17p13.3 region. However only 2/19 (10.5%) clinically low grade tumours (AS) had such a loss (Table 1 and Figure 1 ). The probability of having such or morè same-sided' extreme outcome just by pure chance (Fisher's exact one-tailed probability) is 0.02. The number of AA was too few for independent analysis.
Heterozygosity status of p53 (17p13.1) locus
Since the informativeness of the individual polymorphic regions in p53 locus (intron 1, exon 4 and intron 6) were poor, it was studied sequentially in one of the three loci in p53 till an informative result was obtained.
For the pentanucleotide repeat-containing polymorphic sequence in intron 1, the region was PCR ampli®ed using the same conditions (1 min at 948C, 1 min at 648C, 1 min at 728C for 33 cycles) and primers(ACT CCA GCC TGG GCA ATA AGA GCT and ACA AAA CAT CCC CTA CCA AAC AGC) as described (Hahn et al., 1993) and analysed in a Ethidium Bromide (EtBr) stained, 15% non-denaturing polyacrylamide gel after electrophoresis.
Regions of exon 4 and intron 6 having polymorphic restriction enzyme site for BstUI and MspI, respectively, were separately PCR ampli®ed according to an established protocol (Largey et al., 1993) . For the exon 4 region, the primers used were GAT GCT GTC CGC GGA CGA TAT T and CGT GCA AGT CAC AGA CTT GGC and the conditions were 35 cycles of 1 min at 948C, 1 min at 578C and 30 s at 728C. The primers, AGG TCT GGT TTG CAA CTG GG and GAG GTC AAA TAA GCA GCA GG, were used for 35 cycles of 1 min at 948C, 1 min at 608C and 30 s at 728C to PCR amplify the intron 6 region. The PCR products were extracted once by chloroform-isoamyl alcohol (24 : 1) and precipitated by 80% ethanol at 7708C for 1 h. After drying, DNA was digested with the appropriate restriction enzyme in its buer; BstUI for exon 4 and MspI for intron 6; and further analysed by Figure 1 Representative photograph of heterozygosity status of (a) D17S379 (17p13.3) and (b) p53 (17p13.1) loci in some of the astrocytic tumours studied. (AS, astrocytoma; AA, anaplastic astrocytoma: GBM, glioblastoma multiforme; (b)/(t), PCR product from DNA of blood/microdissected tumour; LOH/NLOH, loss/no loss of heterozygosity; I1/E4/I6, intron 1/exon 4/intron 6 of p53) 17p13.3 locus in astrocytic tumours P Chattopadhyay et al agarose gel electrophoresis after EtBr staining for allelespeci®c restriction fragments. 7/19 (37%) AS and 11/23 (48%) clinically highly malignant astrocytic tumours (AA and GBM) showed LOH at at least one of the sites (Table 1 and Figure 1 ). Fisher's one-tailed P value of such an outcome is 0.34. Association between LOH of D17S379 and of p53 was poor (P=0.24).
Sequencing of p53 gene
Since mutations of the p53 gene are commonest in exons 5, 6, 7, 8 and 9, these were sequenced in the ®ve tumours which showed LOH of D17S379 locus but not of the p53 region. DNA was separately ampli®ed using published primers and conditions (Gaidano et al., 1991) . The ampli®ed products were run in a 5% polyacrylamide gel, the appropriate bands were cut out and DNA was eluted. This was sequenced using Dye Terminator Cycle sequencing chemistry in a ABI Prism 373 sequencer (Perkin Elmer, USA).
None of the tumours with LOH of D17S379 but no LOH of p53, showed any mutation of the p53 gene in these exons.
Heterozygosity status of D17S379 and p53 in a case of AA with heterogenous histological features
In a case of anaplastic astrocytoma, two histopathologically distinct areas of the tumour separated by a region of normal tissue were seen under the microscope. While one area had the typical features of AA (hypercellularity with mitoses, nuclear pleomorphism, gemistocytic changes and giant cells) the other area was histologically less malignant in character (without any of the above changes). DNA extracted from the region of the section with a more malignant appearance had LOH of D17S379 while no such loss was seen in the other. However, both areas retained heterozygosity of p53 locus (Figure 2 ) and had no mutation in the exons 5 to 9 of p53 gene.
The preferential association of LOH of D17S379 (P=0.02) with those grades of astrocytic tumours which have a more malignant histopathology and poor clinical outcome (AA and GBM) is suggestive of the role of a tumour suppressor gene in the short arm of chromosome 17, other than p53, in astrocytic tumour progression. It is apparent from the lack of association between LOH of p53 (17p13.1) and D17S379 (17p13.3) that one is not the bystander eect of the other. While the involvement of the 17p13.3 region has been suspected earlier (Frankel et al., 1992; Saxena et al., 1992) , our observations suggest that the region may, independent of p53 involvement, in¯uence the histological appearance and clinical outcome of astrocytic tumours, biasing it towards a more malignant character. This is supported by the observation in a case of anaplastic astrocytoma with heterogenous histopathological appearance: P53 status (both heterozygosity and sequence) being unchanged, the more malignant area had LOH of D17S379 while the lesser malignant area did not. It is also of relevance to the frequently observed phenotypic heterogeneity of astrocytic tumours, especially the higher grades; while all the observed variations in the histology within a tumour may not have a genetic basis, at least some of it could be due to alterations at 17p13.3.
In our study, LOH at p53 was observed almost equally in all degrees of astrocytic malignancy without any predilection towards any particular phenotype. Hence, it may be an early and common event in astrocytic tumorigenesis. This is in accordance to the deduced sequence of genetic changes in astrocytic tumour progression (Louis and Gusella, 1995). 3) loci of all astrocytomas (AS), anaplastic astrocytomas (AA) and glioblastoma multiforme (GBM) studied in this paper, some of which are shown in Figure 1 . *AA showed heterogeneity both in microscopic appearance and genetic analysis as shown in Figure 2 . (LOH/NLOH, loss/no loss of heterozygosity; NI/NA, not informative/ampli®ed) 17p13.3 locus in astrocytic tumours P Chattopadhyay et al
It is tempting to speculate that while p53 inactivation is one of the early genetic events in a major subset of astrocytic tumours irrespective of the grading at presentation, the inactivation of a putative antioncogene in 17p13.3 like HIC-1 (Wales et al., 1995) or those suspected in ovarian carcinoma (Schultz et al., 1996) may push a astrocytic tumour of less malignant phenotype towards a more malignant one, or, if occurring early enough, may cause direct progression to`de novo' glioblastoma. Further studies are in progress to con®rm this hypothesis in recurrent cases of astrocytic tumours. The 
